<DOC>
	<DOCNO>NCT01218971</DOCNO>
	<brief_summary>This Phase 3 multicenter extension Alkermes ' Study ALK21-003 ( NCT01218958 [ base study ] ) evaluate safety Medisorb速 naltrexone ( VIVITROL速 ) administer every 4 week 48 week ( 13 injection ) alcohol-dependent adult complete Study ALK21-003 .</brief_summary>
	<brief_title>ALK21-003EXT : An Extension Study ALK21-003 ( NCT01218958 ) Test Long-term Safety Medisorb速 Naltrexone ( VIVITROL速 )</brief_title>
	<detailed_description>All participant study receive Medisorb naltrexone double-blinded dose strength ( ie , 190 mg 380 mg ) ; participant receive placebo . Participants receive Medisorb naltrexone Study ALK21-003 ( NCT01218958 ) continue receive dose strength extension study . Those received placebo Medisorb naltrexone 190 mg base study give Medisorb naltrexone 190 mg . Participants receive placebo Medisorb naltrexone 380 mg base study give Medisorb naltrexone 380 mg . Neither identity dose treatment receive base study , Medisorb naltrexone dose strength ( 190 mg 380 mg ) receive extension reveal participant , investigator , blind member clinical study team conduct base study extension . All participant encourage receive standardized biopsychosocial support clinic visit throughout study ; however , unlike base study , participation mandatory . Participants eligible extension study receive 6 injection study drug base study ; receive Medisorb naltrexone base study also receive 13 injection extension therefore duration exposure approximately 76 week ( ~1.5 year ) upon completion extension . For participant receive placebo base study , maximum duration exposure approx . 48 week ( 1 year ) .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Primary Completed study drug treatment Study ALK21003 ( base study [ NCT01218958 ] ) Written informed consent extension study Stable address telephone ; reconfirmation contact 's address phone Women childbearing potential must agree continue use approve method birth control throughout study participation Primary Positive urine drug screen opioids Visit 1 Early termination study drug base study Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Alcohol Dependence</keyword>
</DOC>